Barbara Klencke is Chief Medical Officer at Sierra Oncology, Inc. (SRRA). They have made 5 open-market trades across 2 companies since 2019, most recently 2026-06-16.
CIK 0001647647
5 open-market purchases totalling $322K since 2019, never a sale. Across 5 scored buys the stock is down 9.3% at ninety days, and 16.2 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 20% | 40% |
| Avg Move | +4.6% | -0.8% | -9.3% |
| Alpha | +3.6% | -1.9% | -16.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TCRX | BUY | 2024-09-23 | 2024-09-24 | $5.29 | $26K | +6.6% | -3.9% | -41.8% |
| TCRX | BUY | 2024-08-23 | 2024-08-27 | $5.61 | $56K | +3.5% | -12.3% | -20.3% |
| TCRX | BUY | 2023-12-14 | 2023-12-18 | $5.08 | $25K | +23.8% | +23.6% | +45.0% |
| SRRA | BUY | 2020-08-18 | 2020-08-18 | $12.23 | $113K | -7.0% | -9.1% | +10.7% |
| SRRA | BUY | 2019-08-22 | 2019-08-26 | $0.44 | $101K | -4.0% | -2.4% | -40.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.